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A b s t r a c t
Introduction: Renal denervation (RD) can lead to a significant and sustained decrease in mean values of arterial blood pressure 
(BP). However, there is still a subset of patients without a significant BP drop after RD (non-responders).
Aim: To compare characteristics of RD responders to RD non-responders and to identify the clinical predictors of BP reduction.
Material and methods: Thirty-one patients with diagnosed resistant hypertension underwent RD. Three years after RD the 
analysis of BP reduction was performed in regard to the baseline patient characteristics.
Results: After 3 years’ follow-up a 10% or more reduction of systolic baseline BP was observed in 74% of patients. Ten percent or more 
reduction of diastolic baseline BP was observed in 71% of patients. Among responders we observed the following risk factors: hypercho-
lesterolemia in 70%, body mass index (BMI) > 30 kg/m2 in 55%, diabetes mellitus in 35%, current smoking in 5%. Comorbidity included 
coronary artery disease (CAD) in 30%, cardiomyopathy in 10%, chronic obstructive pulmonary disease (COPD) in 10%, renal insufficiency 
in 10%, and ventricular arrhythmia in 5%. Among non-responders we observed the following risk factors: hypercholesterolemia in 38%, 
diabetes mellitus type 2 in 38% and BMI > 30 kg/m2 in 86%. Comorbidity included CAD in 50% and cardiomyopathy in 13% of patients.
Conclusions: A 10% reduction of systolic baseline BP was observed in 74% of patients 3 years after renal denervation. Clinical 
factors like COPD, chronic kidney disease 3a, female sex and hypercholesterolemia increase the chances of effective reduction of BP.
Key words: hypertension, resistant hypertension, renal denervation.
S u m m a r y
Catheter-based renal nerve ablation with radiofrequency energy via the renal artery can lead  to significant and sustained 
decrease in mean values of arterial systolic and diastolic blood pressure (BP) in patients with resistant hypertension. However, 
there is still a large group of non-responding patients, without significant blood pressure changes after renal denervation (RD). 
The reason of non-responsiveness to RD remains still to be clarified. The aim of the study was to retrospectively compare RD 
responders patients to RD non-responders and find predictors of non-responsiveness for RD as well as clinical factors that might 
have direct impact on the blood pressure reduction to increase the chances of procedural success. Three years after procedure, 
mean BP value remained successfully reduced (> 10% reduction of baseline BP) in 74% of systolic BP and in 71% of diastolic 
BP. Clinical factors like chronic obstructive pulmonary disease, chronic kidney disease 3a, female sex and hypercholesterolemia 
increase the chances of effective reduction of BP.
Introduction
Catheter-based renal nerve ablation with radiofre-
quency energy via the renal artery can lead to a signif-
icant and sustained decrease in mean values of arterial 
systolic and diastolic blood pressure (BP) in patients with 
resistant hypertension (systolic BP < 160  mm Hg). The 
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first procedure of renal denervation (RD) was performed 
by Krum et al. in 2009 [1]. The clinical trials Symplicity I 
and Symplicity II have shown that 84% of patients af-
ter RD had a significant decrease of BP, reaching mean 
systolic and diastolic depression by 30 and 14 mm Hg 
[1, 2]. Effective BP lowering therapy can lead to several 
subsequent benefits including reduction of cardiovascu-
lar mortality and morbidity [1–4] but also improvement 
of quality of life [5]. However, there is still a large group 
of non-responding patients, without significant blood 
pressure changes after RD. The first short-term results 
showed that 84% of the patients had BP ≥ 10 mm Hg 
and 39% had desirable BP (≤ 140 mm Hg) [1]. The reason 
for non-responsiveness to RD still remains to be clarified. 
Aim
The aim of the study was to retrospectively compare 
RD responder patients to RD non-responders and find 
predictors of non-responsiveness for RD as well as clini-
cal factors that might have a direct impact on the blood 
pressure reduction to increase the chances of procedural 
success.
Material and methods
Patients and procedure
All patients enrolled in the study were part of the HTN-1 
and HTN-2 trials population. Adult patients with resistant 
arterial hypertension with systolic blood pressure over 
160 mm Hg, receiving full doses of three antihypertensive 
drugs (including a diuretic) for at least 2 weeks before en-
rollment and with an estimated glomerular filtration rate 
over 45 ml/min who met all inclusion/exclusion criteria 
were eligible for this study. The presence of resistant ar-
terial hypertension was defined as mean brachial artery 
seated systolic pressure above 160 mm Hg during out-pa-
tient department visits, despite historical compliance with 
at least three anti hypertensive drugs (including a diuretic) 
in optimal doses. Blood pressure measurement was per-
formed in accordance with Joint National Committee VII 
guidelines [6]. Measurements were performed each time 
by the same person, sitting, in triplicate and then aver-
aged. The technique of renal denervation has recently 
been described [7–10]. After standard femoral vascular 
access, the SIMPLICITY catheter (Ardian Inc. USA Com-
pany, currently Medtronic Inc., USA) was introduced into 
each renal artery. During the procedure, a standard dose 
of unfractionated heparin was used. Six radiofrequency 
ablations at 8 W lasting up to 120 s each were performed 
in both renal arteries. Supplied energy, tip temperature 
and impedance were monitored by the catheter system in 
response to a predetermined algorithm during the proce-
dure. Follow-up visits were performed at 1, 3, 6, 9, 12, 18, 
24 and 36 months after the index procedure. Blood pres-
sure (systolic, diastolic, pulse pressure) measurements 
were performed according to the methodology described 
earlier. Blood count, electro lytes, urea, creatinine, urine 
and physical examinations including orthostatic BP mea-
surements were performed. During the entire study major 
adverse events (death, stroke, myocardial infarction) or 
other outcomes associated with the procedure were mon-
itored. Three years after the procedure we assessed the 
percentage reduction of the mean baseline blood pressure 
value. Patients were assigned to the “non-responders” 
group if the percentage reduction of systolic blood pres-
sure was ≤ 10% than the baseline. Patients were assigned 
to the “responders” group if the percentage reduction of 
systolic blood pressure was at least 10% of mean systolic 
BP. Written informed consent was obtained from all pa-
tients. The study was approved by the institutional ethical 
board (two separate ethics committee approvals since the 
patients attended the SYMPLICITY HTN-1 and SYMPLICITY 
HTN-2 studies).
Analysis
1. Multiple regression analysis of all factors was per-
formed to find any determinants of BP reduction.
2. The group of patients with BP reduction after RD 
(responders) was compared to the group of patients 
without BP reduction after RD (non-responders).
Statistical analysis
Continuous variables were checked for normal dis-
tribution with the Shapiro-Wilk test. Data are expressed 
as mean ± standard deviation or median (interquartile 
range) unless otherwise stated. To assess the differenc-
es between two continuous variables, Student’s t-test 
(for normally distributed values), or the Mann-Whitney 
U-test (for non-normally distributed values) was ap-
plied. To assess the differences between three continu-
ous variables, the ANOVA test (for normally distributed 
values) or the Kruskal-Wallis-test (for non-normally dis-
tributed values) was applied. Categorical variables were 
compared by the c2 test or Fisher’s exact test, as ap-
propriate. Multiple regression was calculated to assess 
the relationship between one dependent variable and 
one or more independent variables. Statistical analysis 
was performed with Statistica 10.0 (StatSoft, Tulsa, OK, 
USA). A two-sided p-value < 0.05 was considered statis-
tically significant. 
Results
Before the procedure systolic BP from 160 to 170 mm Hg 
was present in 35.5% of patients; systolic BP above 
170 to 180 mm Hg was present in 48.4% of patients; 
systolic BP above 180 mm Hg was present in 16.1% of 
patients. Patients’ characteristic are presented in Table I. 
After 3 years of follow-up a  10% or more reduction of 
systolic baseline BP was observed in 74% of patients. 
A  10% or more reduction of diastolic baseline BP was 
observed in 71% of patients. The mean value of sys-
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tolic BP ranged from 110 to 211 mm Hg (mean value: 
149.69 mm Hg) and it was 25.23 mm Hg lower than 
baseline BP. The mean percentage reduction was 14% in 
all patients. The mean value of diastolic BP ranged from 
64 to 119 mm Hg (mean value: 85.17 mm Hg) and it was 
14.65 mm Hg lower than baseline BP. The percentage 
reduction was 14%. Before ablation the mean systolic 
BP value of three measurements ranged from 162 to 
212 mm Hg (mean value: 174.91 mm Hg). Target systolic 
BP ≤ 140 mm Hg was achieved in 35% and target diastol-
ic BP ≤ 90 mm Hg was achieved in 71% of patients. Tar-
get systolic and diastolic ≤ 140/90 mm Hg was achieved 
in 35% of patients (Figure 1). Relationships between per-
centage reduction of baseline systolic BP and risk fac-
tors are present in Table II. A 20% reduction of baseline 
systolic blood pressure was observed in 35% of patients 
(high response patients). A reduction from 10% to 20% 
of baseline systolic blood pressure was observed in 39% 
of patients (normal response patients). Twenty-six per-
cent of patients had no response for renal denervation. 
Response patients – > 10% baseline systolic 
BP reduction
Twenty-two (71%) patients had > 10% reduction of 
mean baseline systolic BP. There were 10 females and 
12 males (45% female and 55% male) in the response 
group. Patients’ age ranged from 43 to 76 (mean value: 
57.04), weight ranged from 74 to 122 kg (mean value: 
94.7 kg), height ranged from 159 to 184 cm (mean value: 
169.3 cm) and body mass index (BMI) ranged from 23.36 
to 39.41 kg/m2 (33.02 kg/m2). 
Observed risk factors in this group were: hypercholes-
terolemia in 70%, BMI >30 kg/m2 in 55%, diabetes melli-
tus in 35%, current smoking in 5%. Comorbidity included 
coronary artery disease (CAD) in 30%, cardiomyopathy 
in 10%, chronic obstructive pulmonary disease (COPD) in 
10%, renal insufficiency in 10%, and ventricular arrhyth-
mia in 5%. Multivariate logistic regression analysis of risk 
factors in response patients is presented in Table II.
Non-response patients 
Eight (26%) patients did not respond to renal dener-
vation. This group consisted of 2 females and 6 males 
(25% female and 75% male). Patients’ age ranged from 
31 to 72 (mean value: 56.1), weight ranged from 83 to 
145 kg (mean value: 99.14 kg), height ranged from 160 
to 176 cm (mean value: 168.86 cm) and BMI ranged from 
29.39 to 46.81 kg/m2 (34.56 kg/m2). Observed risk fac-
tors in this group were: hypercholesterolemia in 38%, 
diabetes mellitus type 2 in 38% and BMI > 30 kg/m2 in 
86%. Comorbidity included CAD in 50% and cardiomyop-
athy in 13% of patients. 
Differences between clinical factors in regard to re-
sponders and non-responders are presented in Table III.
Table I. Baseline patients’ characteristics
Variable Value
Sex (female) 38.7%
Age (mean) [years] 31–72 (57.3)
BMI (mean) [kg/m2] 23.36–46.81 (33.0)
Weight [kg] 77–145 (94.7)
Height [cm] 160–184 (169.4)
CAD 24.1%
Cardiomyopathy 6.9 %
Ventricular arrhythmia 6.9%
Hypercholesterolaemia 62.1%
Diabetes mellitus type 2 31.0%
COPD 6.9%
Obesity 51.7%
Renal insufficiency 4.4%
 12 24 36
Time [months]
 Systolic BP ≤ 140 mm Hg          Diastolic BP ≤ 90 mm Hg
 Systolic/diastolic BP ≤ 140/90 mm Hg
Figure 1. Percentage of patients who achieved tar-
get systolic, diastolic and systolic/diastolic blood  
pressure values 12, 24 and 36 months after the 
procedure
BP – blood pressure.
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Table II. Multivariate logistic regression analysis 
of risk factors in response patients group
Variable Odds ratio 95% confidence 
intervals
P-value
Age 1.046 0.9405–1.1633 0.4
Female sex 3.0177 0.3565–25.5471 0.31
CAD 0.14 0.0146–1.3397 0.08
COPD 0.4217 0.0121–14.6716 0.63
DM2 1.0904 0.0973–12.2245 0.94
Obesity 0.9879 0.1002–9.7389 0.99
DM2 – diabetes mellitus type 2, CAD – coronary artery disease, COPD – chronic 
obstructive pulmonary disease.
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Discussion
Radiofrequency renal nerve ablation is effective treat-
ment in patients with resistant hypertension by reducing 
the level of blood pressure [1, 2, 8, 10]. Patients with re-
sistant hypertension are at a higher risk of cardiovascular 
events and end-organ damage as compared to patients 
with adequately controlled hypertension [11]. The effica-
cy of the RD procedure has been assessed in several large 
studies. The Symplicity HTN-1 and randomized Symplici-
ty HTN-2 trial demonstrated that RD is feasible, effective 
and safe in the treatment of resistant hypertension. In 
both studies, no adverse effects of RD on renal function 
were observed [1, 2]. However, the Symplicity HTN-1 and 
HTN-2 trials did not include only patients with bilateral 
single arteries. Further research showed that BP reduc-
tion can also be achieved in patients with accessory renal 
arteries [12]. The Symplicity HTN-3 trial suggested that 
6 months after RD there were no significant differences 
in reduction of systolic BP in office or 24-hour ambulato-
ry measurements as compared with a sham control [13]. 
The results of the Symplicity HTN-3 trial did not confirm 
the results of previous registries and trials with a poten-
tially overestimated treatment effect; however, several 
limitations of the study design might have influenced the 
clinical outcomes [14, 15]. On the other hand, Symplicity 
HTN-3 confirmed the safety of the RD procedure. Based 
on the results of individual analyses, we can conclude 
that the final effect of RD will depend on many factors 
and this procedure may not be suitable for all patients. 
Identifying predictors which make RD effective is im-
portant to select patients who will respond adequately 
to treatment. Due to important uncertainties about RD, 
more research is required to provide conclusive evidence 
for antihypertensive long-term effects, safety, clinical 
outcomes and quality of life (QoL) improvement after RD. 
The additional benefits of RD observed in other studies 
were reduction of left ventricle mass and improvement of 
diastolic function. These might have important prognos-
tic implications for patients with resistant hypertension 
at high cardiovascular risk [16]. Other studies have sug-
gested a reduction in heart rate over 6 months [1, 17], as 
well as a positive effect on renal function [18], glucose 
metabolism and insulin sensitivity after RD [19]. In the 
present study, 3 years after the procedure, the mean BP 
value remained successfully reduced (> 10% reduction 
of baseline BP) in 74% of cases for systolic BP (response 
patients) and in 71% of cases for diastolic BP. Thirty-four 
percent of patients had > 20% reduction of baseline sys-
tolic BP, 39% had a  10% to 20% reduction of baseline 
systolic BP and 26% had less than a 10% reduction or 
the mean systolic BP was higher than the baseline BP 
(non-response patients). After renal denervation the 
systolic BP reduction was highest in the female group 
Table III. Comparison of clinical factors between response patients and non-response patients
Variable Response patients Non-response patients P-value
Sex (female) 40.9% 25.0% 0.55
Age (mean) [years] 43–76 (57.0) 31–72 (56.1) 0.32
BMI (mean) [kg/m2] 23.36–39.41 (33.0) 29.39–46.81 (34.6) 0.94
Weight [kg] 74–122 (94.7) 83–145 (99.14) 0.71
Height 159–184 (169.3) 160–176 (168.86) 0.70
CAD 27.2% 50.0% 0.57
Cardiomyopathy 9.1% 12.5% 0.66
Ventricular arrhythmia 4.5% 0% 0.63
Hypercholesterolemia 63.6% 37.5% 0.24
Diabetes mellitus type 2 55.50% 37.5% 0.75
COPD 9.1% 0% 0.91
Obesity 63.6% 87.5% 0.67
Current smoker 4.5% 0% 0.69
CKD: 0.13
CKD 1 50% 50%
CKD 2 41.9% 50%
CKD 3a 9.1% 0%
BMI – body mass index, CAD – coronary artery disease, CKD – chronic kidney disease, COPD – chronic obstructive pulmonary disease.
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compared to the male group. Women were more fre-
quently in the group of response patients (49% women 
vs. 51% men) whereas men were more frequently in the 
group of non-response patients (25% women vs. 75% 
men). It should be noted that female sex is associated 
with the highest risk of resistant hypertension [19]. In 
our study, renal denervation in women led to a 16% re-
duction (28.25 mm Hg) and in men to a 13% reduction 
(23.28 mm Hg) of baseline systolic BP. There was a trend 
towards better responsiveness for RD in older and tall-
er patients and non-responsiveness in obese patients. 
However, there was not significant in the formal statis-
tical sense (p < 0.05). The prevalence of hypercholester-
olemia was higher in response patients (64%) compared 
to non-response patients (38%). Hypercholesterolemia is 
not a  risk factor for resistant hypertension, but it may 
lead to vascular disease such as atherosclerosis or renal 
artery stenosis which can cause resistant hypertension 
[20]. Moreover, systolic BP reduction is more difficult to 
achieve in older patients [20]. In our study, renal denerva-
tion in all hypercholesterolemia patients led to a 16% re-
duction (28.28 mm Hg) of baseline systolic BP. Prevalence 
of diabetes type II, commonly associated with hyperten-
sion, was higher in response patients (present in 55.5%) 
compared to non-response patients (37.5%). Increased 
levels of insulin resistance cause a proportional increase 
in severity of hypertension. Patients with increased sym-
pathetic nervous activity and vascular smooth muscle 
cell proliferation present increased sodium retention 
[21]. Therefore, in diabetes patients, denervation of sym-
pathetic nerves decreases the level of sodium retention. 
Also diabetic patients need more antihypertensive med-
ications (range: 2.8–4.2) to achieve target BP compared 
to non-diabetic patients [22]. Preliminary studies have 
shown that renal denervation is associated with a reduc-
tion in fasting glucose and insulin levels [23]. In our study, 
renal denervation in all diabetes mellitus type 2 patients 
led to a 17% reduction (29.41 mm Hg) of baseline sys-
tolic BP. Obesity was more frequent in the non-response 
group (present in 87.5%) compared to response patients 
(63.6%). Also, higher BMI values were present in non-re-
sponse patients (34.56 kg/m2) compared to response pa-
tients (33 kg/m2). There were no significant differences 
between groups. Obesity is the main lifestyle risk factor 
for resistant hypertension [24] and with high BMI is as-
sociated with more severe hypertension and increased 
likelihood of never achieving optimal blood pressure [25]. 
It is assumed that pathophysiological increased activa-
tion of the sympathetic nervous system caused by obesi-
ty is one of the main reasons for resistant hypertension 
[26]. A recent study showed that renal denervation led to 
suppression of renal sympathetic nerve activity and re-
duction of total body noradrenaline [1, 26]. In our study, 
renal denervation in all obese patients led to a 13% re-
duction (22.15 mm Hg) of baseline systolic BP. Coronary 
artery disease was more frequent in non-response pa-
tients (50%) compared to response patients (27%). A re-
cent study suggested that renal denervation, despite BP 
reduction, also has beneficial effects on heart disease. 
Improvements in symptoms and exercise capacity in pa-
tients with chronic systolic heart failure were confirmed 
by Davies et al. [27]. Other benefits for the cardiovas-
cular system after renal denervation are: improvement 
of cardiac diastolic function, reduction of left ventricular 
mass and reduction of the augmentation index [28, 29]. 
The theoretical potential of renal denervation in cardiac 
arrhythmia is currently being investigated [30].
A recent study suggested that renal denervation, de-
spite BP reduction, also has beneficial effects on heart 
disease like the improvement of cardiac diastolic func-
tion, reduction of left ventricular mass, reduction of the 
augmentation index and exercise capacity [21, 29, 30]. 
The theoretically potential of renal denervation on cardi-
ac arrhythmia is currently investigated [30].
Renal insufficiency was observed only in high response 
patients (18%). Renal diseases are a common cause of re-
sistant hypertension [26]. Renal denervation is a potential 
therapeutic option for hemodialysis patients with resis-
tant or difficult to control hypertension. In our study, renal 
denervation in renal insufficiency patients led to a 22% 
reduction (22.93 mm Hg) of baseline systolic BP.
Resistant hypertension is a specific disease with com-
plex etiology often comorbid with other diseases that re-
quire multidisciplinary treatment. Denervation (ablation) 
of sympathetic fibers in renal arteries is an effective and 
safe treatment in resistant hypertensive patients, as has 
been proven by numerous clinical studies. However, there 
is a group of patients who do not respond to treatment. 
Nevertheless, there are numerous groups of patients 
with comorbid disease in whom renal denervation brings 
a number of additional therapeutic and clinical benefits. 
In our opinion, thoughtful selection of patients’ enroll-
ment in the ablation procedure will further enhance the 
benefits of the procedure and extend the range of indi-
cations for renal denervation. Due to the small number 
of patients in our analysis, a multicenter study should be 
performed for more detailed characteristics of patients 
who underwent renal denervation.
Conclusions
A 10% reduction of systolic baseline BP was observed 
in 74% of patients three years after renal denervation. 
Clinical factors like COPD, chronic kidney disease 3a, fe-
male sex and hypercholesterolemia increase the chances 
of effective reduction of BP. However, due to the small 
number of patients, there was no statistically significant 
difference between these factors.
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